Head and neck cancer trials in Germany

In Germany 51 Also abroad 942

51 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Where
Essen, Hanover
Age
18 years and over
People
200
Run by
AIO-Studien-gGmbH
See details and how to joinNCT06380686
Phase 3Taking people
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Where
Giessen, Hanover, Jena, München, Rostock
Age
60 years and over
People
500 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00
Phase 1/2Taking people
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Where
Essen, Leipzig, Stuttgart
Age
18 years and over
People
287 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00
Phase 3Taking people
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Where
Bonn, Essen, Frankfurt Am Main, Giessen, Hanover, Leipzig, Regensburg, Rostock, Ulm
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00
Phase 2/3Taking people
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Where
Aachen, Berlin, Brunswick, Chemnitz, Dresden, Duesseldorf, Essen, Goettingen, Hanover, Karlsruhe, Mainz, Munich, Stuttgart, Ulm
Age
18 years and over
People
650 worldwide
Run by
Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Frankfurt am Main, Giessen
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
Where
Cologne, Frankfurt Am Main, Freiburg im Breisgau, Kiel, Tuebingen
Age
18 years to 80 years
People
150 worldwide
Run by
OncoZenge AB
See details and how to joinNCT07672236 · EU 2025-524386-24-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
No phaseTaking people
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
Where
Nuremberg
Age
18 years to 85 years
People
55
Run by
Simon Jäger
See details and how to joinNCT06929468
Phase 2Not yet taking people in Germany
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
Where
Cologne, Greifswald, Hagen, Hamburg, Würzburg
Age
18 years and over
People
66 worldwide
Run by
University Hospital, Basel, Switzerland
See details and how to joinNCT07840456
Phase 2Taking people
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Where
Cologne, Giessen, Hamburg, Heidelberg, Kiel, Leipzig, Luebeck, Mannheim, Munich, Wuerzburg
Age
18 years and over
People
160 worldwide
Run by
Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00
Phase 3Taking people
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Where
Cologne, Leipzig, Münster
Age
18 years and over
People
260 worldwide
Run by
Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 3Taking people
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Where
Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig, Lübeck, München, Rostock, Tübingen, Ulm, Würzburg
Age
18 years to 130 years
People
1,145 worldwide
Run by
AstraZeneca
See details and how to joinNCT06129864
No phaseTaking people
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Where
Essen
Age
18 years and over
People
850 worldwide
Run by
XEOS Medical
See details and how to joinNCT06970275
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Hamburg, Heilbronn, Munich
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 2Taking people
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Where
Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Heidelberg, Leipzig, Mainz, Muenster, Offenbach Am Main, Regensburg, Rheine
Age
18 years to 64 years
People
257 worldwide
Run by
AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00
Phase 3Taking people
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Where
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt Am Main, Giessen, Hamburg, Hanover, Herne, Homburg, Kiel, Leipzig, Mainz, Muenster, Munich, Regensburg, Rostock, Straubing, Stuttgart, Tuebingen, Ulm
Age
18 years and over
People
214 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT07026474 · EU 2024-520264-33-00
Phase 1/2Taking people
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Where
Berlin, Cologne, Giessen, Goettingen, Hamburg
Age
18 years and over
People
110 worldwide
Run by
Nykode Therapeutics ASA
See details and how to joinNCT06016920 · EU 2022-503055-26-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
No phaseTaking people
App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy
Where
Erlangen
Age
18 years and over
People
148
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06367257
No phaseTaking people
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Where
Erlangen
Age
18 years and over
People
250
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06947668
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Berlin
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00